(5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, hydrochloride | |
---|---|
Trade Name | |
Orphan Indication | Erythromelalgia |
USA Market Approval | USA |
USA Designation Date | 2017-01-30 00:00:00 |
Sponsor | Biogen, Inc.;300 Binney Street;Cambridge, Massachusetts, 02142 |
Related Access Program